To investigate the incidence of nodal metastasis in a consecutive series of patients treated at the authors' institution with highly selective criteria, and to determine the impact that lymphatic mapping and sentinel node biopsy have on the detection of nodal metastases in this carefully selected patient population.
Objective
To investigate the incidence of nodal metastasis in a consecutive series of patients treated at the authors' institution with highly selective criteria, and to determine the impact that lymphatic mapping and sentinel node biopsy have on the detection of nodal metastases in this carefully selected patient population.
Methods
Study patients were selected from the 7,750 breast cancer patients entered into the authors' database from April 1989 to August 2001, based on the following criteria: nonpalpable, T1a and T1b, non-high nuclear grade tumors, without lymphovascular invasion.
Results
Of the 7,750 patients in the database 1,327 (17%) were found to have T1a and T1b lesions. Three hundred eighty-nine patients were confirmed to meet all four selection criteria. This represents 5% (389/7,750) of the authors' breast cancer pa-tients and 29.3% (389/1,327) of the authors' T1a/T1b tumors. One hundred sixty patients were diagnosed before routine use of lymphatic mapping, and only one patient had a positive axillary lymph node. Two hundred twenty-nine patients underwent lymphatic mapping and sentinel lymph node biopsy, and 10 had a positive axillary lymph node. The difference in proportions of nodal positivity between the mapped and unmapped patients was significant.
Conclusions
This study clearly demonstrates the ability of lymphatic mapping and a more detailed examination of the sentinel node to increase the accuracy of axillary staging. It has been argued that this highly selected group of breast cancer patients possessing retrospectively identified "favorable" characteristics does not require axillary staging. This select population represents only 5% of breast cancer patients in this series, and the authors do not believe they can be accurately identified preoperatively. Therefore, the authors strongly argue for evaluation of the axillary nodal status by lymphatic mapping.
The status of the regional lymphatic basin remains the most powerful predictor of survival in patients with invasive breast cancer. However, axillary lymph node dissection is associated with well-known potential morbidity. As a result, some have proposed selective management of the axilla, omitting routine axillary dissection in patients thought to be at minimal risk of axillary nodal disease. [1] [2] [3] The 2001 National Comprehensive Cancer Network (NCCN) practice guidelines in oncology states "the performance of axillary lymph node dissection may be considered optional in patients who have particularly favorable tumors."
The purpose of this study was to investigate the incidence of nodal metastasis in a consecutive series of patients treated at our institution possessing highly favorable breast cancer characteristics. We also evaluated the impact of lymphatic mapping and sentinel node biopsy on the detection of nodal metastases in this carefully selected patient population.
METHODS
Study patients were selected from the 7,750 breast cancer patients entered into our database from April 1989 to August 2001, based on the following criteria: nonpalpable, T1a and T1b, non-high nuclear grade tumors, without lymphovascular invasion. One thousand three hundred twentyseven patients had T1a and T1b lesions, of whom 494 patients were identified in the database that met the inclusion criteria (Table 1) . IRB approval for chart review was obtained and 466 charts were available for review to confirm the physical findings of a nonpalpable breast mass. The pathology reports were also reviewed on 489 cases to confirm that all lesions were no greater than 1 cm in maximal diameter and none of the cancers were high-grade or had lymphovascular invasion. Lesions with only DCIS and no invasive component were excluded. Three hundred eightynine breast cancer cases met the strict eligibility criteria after careful review, and these patients were the focus of this study.
Beginning in April 1994 all breast cancer patients presenting for definitive surgical treatment to the H. Lee Moffitt Cancer Center with a clinically negative axilla underwent lymphatic mapping using a combination technique previously described. 4 Our accuracy with this technique and the low false-negative rate have also been documented. 5 The axillary status of breast cancer patients found on final pathologic review to have "favorable tumors," as defined above, was documented. The incidence of axillary metastasis was compared in the group who underwent complete axillary node dissection (before the use of lymphatic mapping) with those who underwent lymphatic mapping and sentinel node biopsy.
For each group of patients, the proportion found to have positive axillary lymph nodes was estimated, along with exact 95% confidence intervals computed by the method of Clopper and Pearson. These proportions were compared using the Fisher exact test at the two-sided 0.05 significance level. All calculations were accomplished using SAS, version 8.2.
RESULTS
Of the 7,750 patients in the database, 1,327 (17%) were found to have T1a and T1b lesions. Four hundred ninetyone T1a/T1b patients met the initial selection criteria (nonhigh nuclear grade, nonpalpable tumors, without lympho-vascular invasion) via the database screening. After review of patient charts and pathology reports, 389 patients were confirmed to meet all four selection criteria. This represents 5% (389/7,750) of our breast cancer patients diagnosed over the previously stated 149-month period and 29.3% (389/ 1,327) of our T1a/T1b tumors. One hundred sixty (160) of these patients with T1a and T1b tumors had definitive surgery before the initiation of lymphatic mapping at this institution, all of whom underwent complete axillary dissection. The other 229 patients underwent lymphatic mapping and sentinel node biopsy. In the group of 160 patients diagnosed before our routine use of lymphatic mapping, only 1 patient meeting all four criteria (Ͻ1%, 95% CI 0.02-3.4%) had a positive axillary lymph node, and this was detected by cytokeratin staining only. Of the 229 who were mapped, 10/229 (4.4%, 95% CI 2.1-7.9%) had positive axillary lymph nodes, 5 with H&E staining and 5 only after cytokeratin staining of the sentinel nodes. The difference in proportions of nodal positivity between the mapped and unmapped patients was significant (P ϭ .03) ( Fig. 1 ). Of the 11 patients with axillary metastases, 7 were T1b and 4 were classified as T1a.
DISCUSSION
Tumor size is the single most important primary tumor indicator of the risk of metastatic regional lymph node involvement. Despite the study of multiple other indicators of prognosis, including S-phase fraction, DNA index, hormonal receptor status, and HER2/neu expression, no factor has proven to be more reliable than the simple TNM staging system.
Only 5% of 7,750 patients in our invasive breast cancer series had non-high-grade, nonpalpable tumors, 1 cm or less in size, with no lymphvascular space invasion. Only 1 of 160 who underwent complete axillary dissection before the routine use of lymphatic mapping and sentinel lymph node biopsy proved to have an axillary metastasis. Ten of the 229 (4%) who underwent lymphatic mapping with sentinel lymph node biopsy had positive axillary nodes (5 by conventional H&E evaluation and 5 only with cytokeratin evaluation).
Many difficulties are operative in attempting to omit axillary lymph node staging in clinical practice based on a retrospective analysis such as this and those described by Silverstein and Barth. 1 Key information such as final tumor size, grade, and presence or absence of lymphovascular invasion will not be known when patients present at initial surgical consultation. Patients with well-circumscribed mammographically detected or palpable tumors 1 cm or less in size and of low grade (on core biopsy or FNA) may be upstaged at the time of definitive surgery, either to a larger tumor size or higher grade than originally diagnosed. In addition, the criterion of lymphovascular invasion would be impossible to detect on FNA and rarely seen on core biopsy. To eliminate axillary node evaluation at the definitive sur- gical procedure based on preoperative biopsy and clinical assessment suggesting a "favorable" tumor would require a return to the operating room for a second surgical procedure in many patients. If a lumpectomy were performed, sentinel node biopsy would be possible but potentially less sensitive, and if a mastectomy had been performed, sentinel node biopsy would be impossible. The mastectomy patients would be subjected to a complete node dissection with all its incumbent morbidity, as opposed to a sentinel node biopsy that could have been performed at the original "definitive" procedure for all of the patients. Similar observations have been made for DCIS by these and other authors that significant upstaging can and does occur on final pathologic evaluation following initial biopsy, 6 -9 arguing as well that lymphatic mapping should be performed in all patients with breast cancer at the time of definitive surgery. Our study confirms the findings of Barth and Silverstein that favorable breast cancers have a very low incidence of axillary metastasis. Breast cancer patients with an excellent prognosis can be identified from a retrospective review of a large database. However, we are not convinced this can be translated into a practical prospective approach to the breast cancer patient whereby staging of the axilla is selectively omitted.
This study represents a very select group of breast cancer patients. In the series by Barth et al., only 13% of the 918 patients reviewed fit their retrospective criteria for having a significantly low risk of axillary metastasis, and it is in this select group they argue evaluation of the axillary nodal status could be avoided. 1 Similarly, in Silverstein et al.'s review of 2,282 breast carcinomas, only 189 (8.3%) fit into the extremely-low-risk group. 3 Clearly, most tumors less than 1 cm do not have all of these retrospectively defined favorable criteria. We have previously reported on the results of lymphatic mapping in patients with tumors less than 1 cm: 12.8% of patients with T1a tumors were found to have positive axillary lymph nodes and 23.5% of T1b tumors (though in that report no other selection criteria were used). 10 Most tumors less than 1 cm do not meet all of these "favorable" selection criteria. The evaluation of axillary lymph nodes in the prior studies of "favorable" prognosis breast cancer patients was performed without the benefit of sentinel node biopsy and by routine pathologic evaluation of the lymph nodes, suggesting that serial sectioning and immunohistochemistry was not used. Lymphatic mapping and immunohistochemical analysis has allowed a more sensitive pathologic evaluation of the lymph nodes. This has resulted in an upstaging of approximately 10% to 20% of breast cancer patients who otherwise would have been staged as node-negative. [11] [12] [13] [14] This study clearly demonstrates the ability of lymphatic mapping and sentinel node biopsy to increase the accuracy of axillary staging. This is accomplished at a decreased risk to the patient compared with complete axillary node dissection. Sentinel lymph node biopsy detected axillary disease in a higher proportion of patients than those undergoing complete axillary node dissection (P ϭ .03). This group of patients should benefit from lymphatic mapping and sentinel node biopsy because they will be more accurately staged. Moreover, given their low risk of axillary metastasis, even on sentinel lymph node biopsy, nodal staging can be accomplished and complete axillary node dissection avoided in the overwhelming majority of the patients. We, therefore, do not support omitting evaluation of the axillary nodal status in "favorable" prognosis breast cancer patients based on initial diagnostic evaluation. In this series the patients with detected metastatic axillary disease may otherwise not have been considered for standard adjuvant therapies. We agree with Barth et al.'s related statement: "the controversy on which patients require a complete node dissection is becoming a moot point with the advent and proven accuracy of sentinel node biopsy." 1
CONCLUSIONS
This study clearly demonstrates the ability of lymphatic mapping and sentinel node biopsy to increase the accuracy of axillary staging with minimal morbidity. The ability of the busy practicing general surgeon of this era to accurately and prospectively apply the specific "favorable" criteria to 5% of the breast cancer population is asking a lot of their memory, time, and cognitive judgment, which to be sure would better be applied to learning the new skill set required for lymphatic mapping. These skills could then be applied to all breast cancer patients with equality of purpose, improved metastatic detection, and reduced morbidity. Changing practice patterns preclude the possibility of the prescribed preoperative evaluation from even being able to be done under current circumstances. The radiologist primarily sees many of these patients, and often no documentation of palpability is made before stereotactic core biopsy, after which the hematoma surrounding the biopsy site becomes palpable. The diagnosis is made and treatment decisions must be rendered without accurate sizing, palpability, or preoperative pathologic completeness for evaluation of lymphovascular invasion. Indeed, future study of these param-eters may be impossible, as was found in our own chart review.
Though it has been argued that this highly selected, retrospective, "favorable" group of patients does not require axillary staging, we would strongly argue for evaluation of the axillary nodal status by lymphatic mapping. Indeed, for the patient with positive nodal disease in this "favorable" subset, the survival benefit ascertained with adjuvant therapy would be lost without sentinel node biopsy. I think this paper presented by Charles and Jim has enormous value to the members of the Association, as T1a and T1b lesions, those less than 1.0 cm, together with T1c lesions, which are between 10 and 20 mm, are among the most rapidly increasing frequency of invasive carcinomas in the American female population.
The Biometry Branch of the National Cancer Institute estimates that within 15 years, almost 30% of all of our breast cell cancer will be DCIS, preinvasive. But you just saw from the slide presentation by Dr. Jakub that perhaps as many as 16% of the DCIS patients had positive nodes. This paper, I think, has merit as it has carefully analyzed a small subset, which included the 5% of breast cancer population at the Moffitt with favorable histologic features. And you saw what they were: low-grade tumors, less than 1.0 cm, but without lymphovascular invasion. And this reflects a population in which surgeons, I think, in America are increasingly reticent to do any type of treatment of the axilla.
At Brown, at the Rhode Island Database, the Tumor Registry combined with the Massachusetts Tumor Database, we note that over 1,300 patients with these small-sized lesions were T1a/T1b lesions. Our frequency of nodal metastasis for T1a was 9%, and for T1b it was 19%. So almost one in five T1b lesions had positive nodes.
Further, we have evaluated over 20,000 women at the National Cancer Database of the College, and it is evident that you as Fellows of the American College of Surgeons are reticent to treat the axilla as a woman ages. In analysis of the aging population, over 40% of those over 70 years and over 60% of those over 80 years, the Fellows did not treat the axilla surgically or even consider for sentinel node mapping. Again, it was in an era about 10 years removed when we began to do sentinel node staging. But the importance of this current study is that for 229 patients, as you have seen, T1b/a lesions underwent nodal mapping and confirmed that 4.4% had positive nodes in this highly favorable tumor subset. Now, Dr. Cox has used both histologic staining techniques. He has used cytokeratin as well as H&E. In our study from Brown, we used only H&E and, therefore, this may account for a smaller frequency of node positivity than the authors have indicated, including your DCIS population.
So I have a few questions for the authors. Considering the issue that advanced age represents favorable criteriathat is, as a woman ages, the phenotype of the tumor is more favorable in breast cancer-would the authors consider aborting the sentinel lymph node mapping technique for these elderly patients who present with favorable criteria such as low nuclear grade and without lymphovascular invasion?
Second, you have acknowledged that of the 229 patients who were mapped, 4.4% had positive nodes. Again, you combined IHC with H&E staining. Half your patients with nodal positive histology were IHC positive, half were H&E positive. Using this combination, therefore, you have upstaged a significant frequency of this population. For many clinics in America, including our own at UAB, we do not evaluate IHC of lymph nodes with cytokeratin stains. Therefore, the question I have for you or Jim would be, if you do have IHC positive nodes, do you use that criterion for treatment with adjuvant therapy in these patients?
I enjoyed this contribution and thank the Association for the privilege of the floor.
DR. KELLY M. MCMASTERS (Louisville, KY): Dr. Jakub, Dr. Cox, and colleagues should be congratulated for yet another important analysis of the role of sentinel biopsy for breast cancer. In this analysis, patients with the most favorable invasive cancer that could be identified-that is, those with nonpalpable T1a/b tumors, without high nuclear grade or lymphovascular invasion-had a 4% rate of positive lymph nodes when staged by sentinel lymph node biopsy, compared to less than 1% rate of nodal metastasis when axillary dissection was performed for nodal staging in the past.
Based on these findings, the authors conclude that sentinel lymph node biopsy should be performed even for very favorable invasive breast cancers. I agree with the authors' conclusion, because I think that minimally invasive method of sentinel lymph node biopsy shifts the risk/benefit ratio in favor of nodal staging for early cancers compared to complete axillary dissection. However, I have several questions regarding the manuscript.
First, were the patient populations truly similar in regard to age, median tumor size, histologic subtype, and other prognostic factors? Were T1mic, or invasive cancers with 1 mm or smaller foci of invasion included in the T1a category? In the manuscript, there is no analysis of the characteristics of each patient population, and it is not clear that the two populations are exactly similar.
Second, what else can you tell about the 11 patients in this series with nodal metastases? How do they differ from the rest of the patients? Are there any other clinical or pathologic factors that might have predicted nodal metastases in these patients?
As Dr. Cox and I have discussed many times, the prognostic significance of micrometastases detected in the sentinel lymph node only by cytokeratin immunohistochemistry is highly controversial and remains unproven, as Dr. Bland just mentioned. Until large clinical trials from the American College of Surgeons Oncology Group and the NSABP are completed, it has been recommended that cytokeratin immunostaging of sentinel lymph nodes not be used for clinical decision making.
In the present study, when immunohistochemistry was used, a total of 4% of patients with favorable invasive cancers had sentinel node metastases. This is much lower than the 13% rate of positive sentinel lymph nodes that your group has reported for pure DCIS without microinvasion. If one truly believes that such micrometastases impart a worse prognosis, one would have to conclude that pure DCIS is three times worse than favorable invasive cancer.
With that in mind, how did the finding of immunochemistry-detected micrometastases influence treatment decisions in your patients with these favorable cancers? Did all these patients have an axillary dissection and adjuvant therapy? It would certainly be interesting to evaluate the diseasefree and overall survival curves of the patient populations.
Finally, do you think other factors should be factored into the decision to perform axillary nodal staging for patients with favorable tumors, such as patient age and the potential impact, or lack of impact for some patients, on adjuvant therapy decisions? DR. EDWARD M. COPELAND, III (Gainesville, FL): I also enjoyed that paper. I think Dr. McMasters is pointing out that the 12% incidence of sentinel node positivity in DCIS and the 4% positivity of invasive breast cancer is an important point and speaks to the controversy of using cytokeratin. Let me ask another question, Dr. Cox. If you have a patient with favorable biology and you do not find a sentinel node, would you do an axillary dissection? DR. JAMES W. JAKUB (Lakeland, FL): Dr. Bland asked about patients with increasing age and do we do sentinel lymph node biopsy in those patients with increasing age and favorable tumors. We do. The major reason for that is the low morbidity of the procedure. I think the information gained is significant at little risk to the patient; therefore, the risk/ benefit is much in favor of sentinel lymph node biopsy, as opposed to 10 years ago for complete axillary lymph node dissection in the same patients.
Dr. McMasters asked are we concerned about how the patients are going to get treated, I think is the crux of his last question, if we find cytokeratin disease and the patients have a very favorable tumor. I think that is a very good question. I think what we need to do is to continually evaluate these patients and find the answers to these questions. And we can't be afraid that we are going to find a patient who has DCIS as the final diagnosis and we know that patient has an excellent prognosis, 95% to 99% long-term survival, and a cytokeratin cell may be found in the lymph node. We can't be concerned our medical oncology colleagues are going to overtreat those patients and therefore bury our head in the sand and not look for the sentinel lymph node. It is kind of akin to our pathologists who sometimes wanted to call LCIS lobular neoplasia, because they are afraid the surgeon is going to do something stupid and do a mastectomy because he puts the word "cancer" in LCIS. I think we need to be intellectually honest and I think we need to accurately stage these patients and let the data fall out where it is and let our medical oncology colleagues know of the data, that these DCIS patients have an excellent prognosis and the cytokeratin staining may not be significant. We don't know the answer to those questions yet.
To address the three cytokeratin questions, I think a little historical context needs to be understood of where we came from and where Drs. Cox and Reintgen came from at Moffitt in beginning lymphatic mapping for breast cancer.
Lymphatic mapping for melanoma and sentinel lymph node biopsy in melanoma was approximately 5 years ahead of its application in breast cancer. What we knew before we started lymphatic mapping in breast cancer is that patients who had a false-negative sentinel lymph node in melanoma-in other words, the lymph node was negative on sentinel lymph node biopsy but they had a regional nodal recurrence. When we went back and looked at those patients, their original sentinel lymph nodes, and stained them with immunohistochemistry, we found that 10 of 11 of those patients had positive S-100 cells in the lymph node. And what this says is that the false-negative was not a result of the surgical procedure; it was a false-negative as a result of the pathologic staining techniques that were not available at that time. It was with this knowledge that we approached lymphatic mapping and sentinel lymph node biopsy at Moffitt in 1994.
Knowing that we wanted to avoid false-negatives, if we were going to change the standard of care as was being done across the country, the main thrust was to avoid false-negative biopsies in patients undergoing lymphatic mapping instead of a complete node dissection. We never set out to show that IHC staining is an independent clinical prognosticator. For some, that is what has been promulgated in the literature, but that was not the point of IHC staining; the major point was to avoid false-negatives. And we showed in a paper last year presented at the ASBS and published last month that if you do IHC staining, you will upstage approximately 10% to 20%, and other series have also shown you will find cytokeratin staining in an increased population of patients.
In our 78 patients who had cytokeratin-positive-only cells and went to the operating room for a complete node dissection, 14.5% of them were found to have H&E disease at the time of complete node dissection. These patients would have been falsely staged as N0 had cytokeratin staining not been done. And we have decreased our false-negative rate by 2.5%. That is an absolute risk reduction, not a relative risk reduction. So if your false-negative rate is 5% without cytokeratin staining and now you apply cytokeratin staining and complete node dissection if the cytokeratin is positive, your false-negative rate will now be 2.5%. So that is the major reason.
And you are right, we don't know the answer to cytokeratin staining, and we may not know the answer for 10 to 20 years. And I won't go into that. The discussants know the literature better than I do and the problems with cytokeratin staining in clinical prognostication. That is not the reason we do it, and I need to stress that.
One other point on DCIS. When we went back and looked at our patients who had a complete node dissection, when we were doing that for DCIS back in the '80s, we went back and relooked at their lymph nodes with cytokeratin staining. So these are historical patients with over 10 years of follow-up. And what we found when we looked at those lymph nodes, that a few patients, about 5%, were upstaged with cytokeratin staining. However, that had no clinical significance. The survival in those patients was still the typical 95% to 99% long-term survival of patients with DCIS whether you could find cytokeratin cells in lymph nodes.
So occult micrometastatic disease in DCIS we believe appears to have little clinical significance and we do not recommend chemotherapy, we do not recommend complete axillary lymph node dissection if a patient with DCIS is found to have a cytokeratin-positive-only lymph node. We do believe that the DCIS patients that have an H&E-positive node, that is probably a missed invasive component of the primary tumor, and our pathologists support that.
So as a result, this is our algorithm, our simplified algorithm. Patients, whether DCIS or a 5-cm tumor, undergo a sentinel lymph node biopsy. If the node is negative, no axillary node dissection. If a patient has DCIS, final diagnosis, DCIS and cytokeratin-positive-only cells in the sentinel lymph nodes, we do not proceed with axillary dissection. We did initially, and we stopped because we didn't find any further disease. So that is our clinical decision at this point. If a patient has DCIS or invasive cancer and is found to have an H&E-positive node or a patient with invasive breast cancer who has a cytokeratin-positive-only SLN, we do perform axillary node dissection, and, again, because 14% of these patients will be upstaged at the time of axillary node dissection, and your false-negative rate will be reduced by 2.5%.
In terms of the Dr. Copeland's question, if we have a very favorable tumor and we do a sentinel lymph node biopsy and we don't find the sentinel lymph node. You are talking about 5% of breast cancer patients, and our incidence of not finding a sentinel lymph node is 3%, so 0.05 times 0.03 times that is going to happen, and in that case, which is about one in a thousand, no, I don't think we would proceed. 
